Neobac

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Neobac

Quick Facts

Property Description
Active Ingredients Bacitracin, Neomycin
Form Ointment, Powder
Pharmacological Class Topical Anti-infective / Broad-Spectrum Antibiotic
Common Use Prevention of infection in minor skin injuries
Origin Derived from bacterial sources (microbial)

What is Neobac? Definition and Pharmacological Classification

Neobac is classified as a topical anti-infective agent and a broad-spectrum antibiotic, constituting a combination drug used solely for application to the skin. This medicine is recognized as a first aid antibiotic product and is typically available for topical administration as an ointment or powder. The classification as a broad-spectrum antibiotic signifies that the product is clinically recognized for its essential role in addressing superficial infections caused by diverse bacterial species.

Active Ingredients and Compositional Strategy

This pharmaceutical preparation features the two core active ingredients: Bacitracin (often as the zinc salt) and Neomycin (typically as the sulfate salt). Bacitracin is scientifically defined as a polypeptide antibiotic, while Neomycin is an aminoglycoside antibiotic; both are derived from natural microbial sources. The strategic selection of these two distinct classes confirms the product's adherence to the principle of synergistic formulation. This combination product utilizes an oil-based base/vehicle, such as white petrolatum, in the common ointment form to facilitate local delivery of the compounds.

General Purpose: Why the Combination is Used

The fundamental purpose of this combination is to achieve comprehensive bacterial defense by delivering a synergistic antimicrobial effect against common pathogens. This formulation is specifically intended to aid in the prevention of infection in minor, superficial skin trauma, including small cuts, scrapes, and burns. By targeting both Gram-positive and Gram-negative organisms, the medication helps reduce the localized risk of bacterial proliferation, thereby supporting clean, natural healing.

Regulatory References

  1. MedlinePlus: Neomycin, Polymyxin, and Bacitracin Topical Drug Information

What side effects are possible with Neobac?

Possible Side Effects and Safety Information

The official safety profile for the topical combination of Bacitracin and Neomycin is organized by two main safety concerns: local skin reactions and potential systemic toxicity. Regulatory classifications focus heavily on adverse events linked to the skin.

Adverse Reaction Classification

The most commonly encountered adverse reaction is cutaneous sensitization, an allergic response to the skin, which is occasionally caused by the Neomycin component. Signs of this reaction, such as reddening, swelling, itching, or dry scaling, may appear as a simple failure of the condition to heal [FDA AccessData]. The exact frequency of these hypersensitivity reactions is generally not known in the topical context.

System-Organ Class Primary Adverse Reactions
Skin and Subcutaneous Tissue Disorders Cutaneous sensitization, irritation, rash
Ear and Labyrinth Disorders (Systemic Risk) Ototoxicity (Permanent hearing loss)
Renal and Urinary Disorders (Systemic Risk) Nephrotoxicity (Kidney impairment)

Serious Adverse Reactions and Safety Constraints

Although rare with proper topical use, serious adverse reactions are documented when significant amounts of Neomycin are absorbed into the body. These include permanent sensorineural hearing loss (Ototoxicity) and kidney impairment (Nephrotoxicity) [DailyMed].

Safety constraints prohibit the use of this product in individuals with a known hypersensitivity to either Bacitracin or Neomycin [DailyMed]. The risk of these systemic toxicities, as well as the risk of superinfection, is documented as greater with prolonged use or application over large surface areas of the body [FDA AccessData]. Safety during pregnancy and lactation is not known.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information describes the overdose profile for this topical combination primarily around the risks associated with significant systemic absorption or accidental ingestion.

Documented Overdose Manifestations

Feature Official Regulatory Statement
Acute Symptoms Stomach pain and vomiting are documented following accidental ingestion. Acute exposure to the eyes may result in redness or pain [MedlinePlus].
Severe Outcomes Systemic absorption of the Neomycin component carries a documented risk of irreversible ototoxicity (hearing loss) and nephrotoxic potential (kidney damage) [HPRA SmPC].

When to Seek Immediate Medical Help

The regulatory guidance mandates specific actions if an overdose is suspected or a severe reaction occurs:

  • Accidental Ingestion: Users are explicitly instructed to seek medical help or contact a Poison Control Center right away [DailyMed OTC Label].
  • Severe Reaction: Emergency medical care must be sought right away if a severe systemic reaction, such as difficulty breathing, is observed [MedlinePlus].

Management of significant systemic exposure is generally defined as symptomatic and supportive, and official regulatory information notes that no specific antidote is known. Monitoring requirements in a hospital setting may include assessment of hearing acuity and renal function [HPRA SmPC]. A specific caution is noted for patients with decreased renal function due to heightened risk of systemic toxicity.

Therapeutic Uses of Neobac

What Neobac Treats: Main Uses and Benefits

Neobac is commonly used across therapeutic domains to help address symptoms associated with acute or disruptive episodes caused by bacterial contamination. It is relevant in contexts involving heightened systemic burden, such as conditions presenting with systemic or localized discomfort due to bacterial presence.

This medicine is applied across domains where additional symptomatic support is needed to address localized discomfort and symptoms related to inflammatory or irritative states. It helps manage symptom clusters that may become intense or disruptive, offering supportive relief when symptoms interfere with routine activities.

It is commonly used across conditions presenting with acute episodes, where symptomatic relief and support are needed for symptoms related to inflammatory or irritative states. This treatment provides support that helps ease the overall symptom burden, contributing to improved day-to-day comfort and assisting with maintaining functional stability.

Quick Fact: Supports Management of Localized Discomfort

Indications: It is commonly used across conditions presenting with acute episodes, where symptomatic relief and support are needed for symptoms related to inflammatory or irritative states.

Regulatory References

  1. NIH MedlinePlus overview of Topical Neomycin, Polymyxin, and Bacitracin

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Neobac — Official Regulatory Information

Category Official Regulatory Statement
Populations for whom use is allowed Adults and children are the approved user groups for minor cuts, scrapes, and burns.
Populations for whom use is contraindicated Individuals with a known hypersensitivity or allergy to Bacitracin, Neomycin, or any other ingredient in the formulation.
Age-related eligibility rules Use in children younger than mathbf2 years is often restricted for over-the-counter self-medication; safety and effectiveness may be officially not established in this pediatric group.
Condition-specific eligibility rules Patients with pre-existing kidney disease or severe renal impairment are advised to consult a doctor before use, due to the risk of systemic absorption of the Neomycin component.
Pregnancy and lactation eligibility status Use during pregnancy is advised only if clearly needed (e.g., former Category C caution). Caution is exercised during lactation, as it is unknown if the drug is excreted in human milk.
Eligibility-related restrictions The product is prohibited from application in the eyes or over large areas of the body. Consult a doctor for use on deep wounds, animal bites, or serious burns.

Connection to the Overall Eligibility Profile

Official regulatory documents define who can and cannot use the medicine by establishing Absolute Contraindications based on ingredient sensitivity and site of application. Eligibility is further governed by Conditional Restrictions tied to patient age, the severity of the injury, and the presence of comorbidities like kidney disease, which is necessary due to the documented risk of systemic absorption of the topical neomycin component.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for this combination medicine addresses interactions that may occur following enhanced systemic absorption of Neomycin, particularly when the product is applied to compromised skin such as burns or large denuded areas.

Official Interaction Restrictions

Co-administration with specific medicinal products is restricted due to the potential for additive toxicity. Regulatory documents classify the concurrent or sequential systemic use of other aminoglycoside antibiotics as restricted, given the risk of additive neurotoxicity and nephrotoxicity. Potent diuretics such as Furosemide and Ethacrynic acid should be avoided because of the documented potential to enhance the risk of ototoxicity. Other systemic neurotoxic or nephrotoxic agents, including Vancomycin and Cisplatin, also fall under the restriction for combined use.

Pharmacodynamic Effects and Population Notes

A documented pharmacodynamic interaction exists with neuromuscular-blocking agents; Neomycin absorption may intensify their effects, with a noted risk of respiratory paralysis. Population-specific information indicates that the overall interaction risk is officially noted as being greater in patients with renal impairment due to the potential for drug accumulation. Individuals with neuromuscular disorders and infants/neonates are also identified in official labeling as having increased susceptibility to these systemic interaction effects.

Mechanism of Action

How Neobac Works: The Mechanism of Action

Neobac operates by selectively modulating defined receptor systems that govern specific humoral pathways in the body. Its primary action involves binding to a distinct site on these receptors—a process known as allosteric modulation—which changes the receptor's sensitivity to its natural signals. This action results in a modulation of signal transmission rather than a complete block or activation.


Targeted Modulation of Receptor Systems

This mechanism modifies the early molecular steps within specific receptor- or enzyme-mediated signaling domains, thereby reducing activity within overactive physiological pathways by adjusting the cell's responsiveness. Neobac influences the subsequent chain of molecular events, or signal transduction cascades, that follow receptor engagement.


Influencing Physiological Signaling Dynamics

By intervening in these sequences, the drug modifies the kinetics of signaling sequences, altering downstream effects and promoting signal equilibrium within the targeted pathways. The cumulative effect of Neobac's molecular activity leads to its final functional role: engaging feedback mechanisms that influence signaling dynamics across the affected biological systems. This mechanism contributes to reduced flux of mediator activity and leads to physiological alterations that result from the drug's effect profile.

Dosage and Administration Information

How Neobac is Used

The application of Neobac, a topical anti-infective combination, follows a standardized protocol derived from its official regulatory status. The medicine is provided in two primary dosage forms: an ointment and a powder, and is strictly administered by the topical route to the skin surface. It is intended solely for localized, external use and must not be ingested or applied near the eyes.

Administration and Frequency

The standard regimen involves applying a thin layer of the ointment or powder to the affected skin area. This process is typically repeated one to three times daily, as necessary. Before application, the affected site should be cleaned. The treated area may optionally be covered with a sterile bandage, which is a recognized procedural step in administration guidance.

Use Duration and Constraints

Usage of Neobac is reserved for short-term courses. The official instructions for proper use emphasize that the duration of treatment should generally not exceed seven days (one week) for a single episode. There are no specific label-based adjustments for dose or frequency for older adults or individuals with organ impairment, given the product's short-term, localized application pattern.

Usage Entity Official Regulatory Principle
Route of Administration Topical application to the skin only.
Dosing Schedule Apply a thin layer to the affected area.
Frequency Pattern One to three times daily.
Course Duration Not to exceed seven days.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Neobac


Evidence for Use in Preventing Infection in Minor Skin Wounds

The core evidence for the topical antibiotic combination, including its use in Neobac, is derived from short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies are relevant in trials assessing short-term or episodic symptom patterns and were designed to explore research examining whether its application is associated with lower rates of infection in minor skin trauma.

Studies were designed to explore the incidence of clinical infection in groups receiving the combination versus those receiving an inactive vehicle base (like plain petroleum jelly). Findings were reported as showing that application was associated with a pattern of fewer reported infection incidents in the study populations, compared to the vehicle. This evidence is relevant to the medicine's regulatory classification for this first aid indication. However, evidence from meta-analyses indicates that the absolute difference in infection rates between the combination and inactive controls was reported to be of a lower magnitude.


Follow-up Duration and Long-Term Research

The majority of key clinical studies used in the regulatory review process focus on short-term outcomes. Follow-up durations were typically limited to one week or less, aligning with the initial, acute phase of healing for minor skin trauma.

Long-term effects are not fully established because the research generally does not track individuals beyond this acute period. There is limited information for long-term outcomes, such as the durability of the observed responses after the product is stopped. Research has explored short-term symptom changes, but long-term outcomes are not well characterized, meaning findings describe group patterns observed only during the study period.


Research Gaps and Areas of Uncertainty

While the clinical research is relevant to the product's regulatory designation as a first aid antibiotic, it is subject to several limitations. One key area of uncertainty is that the sample sizes were modest in some of the older foundational trials. Evidence quality varies across studies, and findings were sometimes mixed, particularly when comparing the combination to other topical antibiotic formulations.

Furthermore, studies predominantly focused on its use as a preventative measure in uncomplicated, minor trauma. Comparative evidence is lacking for its use in deep wounds, animal bites, or serious, extensive burns, as these conditions require different forms of medical care and were specifically excluded from the studies. This means research provides context but not individual predictions, and the evidence highlights what is known — and what is still uncertain — about outcomes when used outside the study conditions.

Key Studies & References

  1. Do topical antibiotics improve wound healing? (Includes review of RCTs comparing triple-antibiotic ointment to petrolatum)
  2. Neomycin, Polymyxin, and Bacitracin Topical: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Neobac (FAQ)


Q: How quickly should I expect to see an effect from Neobac?

A: Official product information does not specify an exact time frame for the initial onset of effect. Studies supporting the medicine’s use focus on a short course, generally not exceeding seven days. The product’s function is described as helping to prevent infection while the body is healing.


Q: Does Neobac cause weight gain or loss?

A: According to the official adverse reaction lists, weight changes are not listed among the recognized or commonly reported side effects for the topical use of this medicine. Due to its topical application, the risk of systemic effects is described as minimal.


Q: Is it normal to feel slightly dizzy when first starting Neobac?

A: Official regulatory documents do not describe dizziness in the safety profile for the topical administration of this product. Regulatory guidance advises consulting a healthcare professional if unexpected symptoms occur.


Q: Does Neobac interact with common pain relievers like ibuprofen?

A: The official interaction documents do not list any known specific drug interactions between the topical Neobac combination and common over-the-counter pain relievers, such as ibuprofen. Given the medicine's topical route, official information does not typically list specific drug interactions with common pain relievers.


Q: Is Neobac safe for older adults (senior citizens)?

A: Regulatory information indicates that no specific dose adjustments are typically required for older adults. However, official documents highlight that individuals with pre-existing kidney impairment are subject to a conditional restriction regarding use.


Q: What happens if I miss a dose of Neobac?

A: General regulatory protocol for short-term topical antibiotics suggests applying the missed dose as soon as possible. Dosing protocol generally indicates that if a scheduled application is missed, it should be applied as soon as possible, or skipped if it is close to the next scheduled time.


Q: Can Neobac cause trouble sleeping (insomnia)?

A: Trouble sleeping, or insomnia, is not listed in the recognized or commonly reported adverse reactions for the topical use of this product in official safety documents.


Q: Does Neobac affect my ability to drive or operate machinery?

A: Since the medicine is used topically and is not typically associated with effects on the central nervous system (CNS), official labeling does not describe side effects that would impair a person’s ability to drive or operate machinery.


Q: Are there any specific foods I should avoid while on Neobac?

A: The official regulatory documents regarding interactions do not list any specific foods that must be avoided while using Neobac topically.


Q: Is Neobac addictive or habit-forming?

A: Neobac is not classified as a controlled substance and is not associated with dependency or habit-forming properties in its official regulatory profile.


Q: Why do some people say Neobac gives them stomach issues?

A: This medicine is strictly for topical use on the skin, and it should not be swallowed. The official safety profile focuses on risks to the kidneys and hearing upon systemic absorption. Gastrointestinal side effects are not typically listed for this topical product.


Q: Does Neobac have a black box warning from the FDA?

A: The topical combination product in its common over-the-counter form is not associated with a Black Box Warning in official regulatory documentation. Black Box Warnings are used by the FDA to highlight serious risks.


Q: Is Neobac a brand name or a generic medicine?

A: Neobac is the combination of the active ingredients Bacitracin and Neomycin. This combination is widely available as a generic combination product and is also sold under various trade names.


Q: Does taking Neobac require regular blood tests?

A: No, regular blood testing is not generally required for the short-term topical use of this medicine. This is based on the short-term nature of the therapy.


Q: Can Neobac be used by people with diabetes?

A: Diabetes is not listed as an absolute contraindication for the topical product. However, regulatory guidance suggests that individuals with pre-existing health conditions are advised to consult a healthcare provider before use.


Q: Is it true that Neobac is a newer class of drug?

A: The two active ingredients, Bacitracin (a polypeptide antibiotic) and Neomycin (an aminoglycoside antibiotic), are both well-established classes of medicine derived from microbial sources and are not considered a 'newer class' of drug.


Q: Can I take Neobac if I have high blood pressure?

A: High blood pressure, or hypertension, is not listed as a contraindication or a primary interaction concern for the topical product in official documentation.


Q: Does Neobac interact with herbal supplements like St. John's Wort?

A: The official interaction documents for the topical product do not list specific interactions with herbal supplements such as St. John's Wort.


Q: What are the signs of a serious allergic reaction to Neobac?

A: Signs of local allergic sensitization (a common skin reaction) include persistent reddening, swelling, and itching at the site of application. Warnings note that systemic serious reactions are documented following significant absorption.


Q: Does Neobac affect fertility in men or women?

A: Official documentation does not typically contain conclusive data regarding the effect of short-term topical use of the Neomycin/Bacitracin combination on human fertility.


Q: Is Neobac safe to use if I have kidney problems?

A: Individuals with pre-existing kidney disease or severe renal impairment are advised to consult a healthcare provider before use. Regulatory documents state that consulting a healthcare provider is advised before use, due to the documented risk of systemic Neomycin absorption.


Q: What are the common reasons why a doctor might discontinue Neobac?

A: Treatment is intended for a short course, generally not exceeding seven days. Discontinuation is also indicated if signs of sensitization (worsening skin) or superinfection (a second infection) appear, or if the initial condition fails to heal.


Q: Is there a generic version of Neobac available yet?

A: Yes, the combination of Bacitracin and Neomycin is the standard formulation, and it is widely available in generic form.


Q: Does Neobac interact with birth control pills?

A: Due to its topical application and minimal systemic absorption when used correctly, official documents do not list an interaction with hormonal birth control pills.


Q: How long does Neobac stay in your system after stopping it?

A: When properly applied topically for minor skin trauma, systemic absorption is usually minimal. Official information indicates the product is not expected to accumulate or remain in the body’s system for a prolonged duration.


Q: Does Neobac make you more sensitive to the sun?

A: Photosensitivity (increased sensitivity to the sun) is not listed as a recognized adverse reaction for the topical product in official safety documentation.


Q: Is it possible for Neobac to stop working over time?

A: The risk of superinfection with non-susceptible organisms is documented with prolonged use. This is a regulatory warning indicating that the medicine may not be effective if the bacterial target changes or develops resistance.


Q: What is the legal classification of Neobac (e.g., prescription-only)?

A: The Neomycin/Bacitracin combination is generally classified as an Over-the-Counter (OTC) drug product, meaning it is available without a prescription for first aid use.


Q: Does Neobac have any known interactions with alcohol?

A: The official documentation does not list specific interactions with alcohol for the topical product.


Q: Is there any research looking at Neobac use in children?

A: Regulatory documents state that adults and children are approved user groups for this product. However, use in children younger than two years is often restricted for over-the-counter self-medication.


Q: What if I take Neobac and feel no change at all?

A: Failure of the condition to heal is listed in regulatory safety information as a possible sign of cutaneous sensitization or superinfection. Failure of the condition to heal is a criterion that suggests seeking guidance from a healthcare professional.


Q: Does Neobac cause hair loss?

A: Hair loss is not listed among the recognized or commonly reported adverse reactions for the topical product in official safety documents.


Q: What does official guidance say about the risk of liver damage with Neobac?

A: Official safety guidance focuses on the systemic risks of Nephrotoxicity (kidney impairment) and Ototoxicity (hearing loss) upon significant systemic absorption; liver damage is not listed as a documented systemic risk.


Q: What are the official recommendations for stopping Neobac treatment?

A: The official recommendation is that the course of treatment should not exceed seven days. Official labeling advises that treatment should be stopped if symptoms worsen or a rash appears at the site of application.


Q: Why are people concerned about a specific ingredient in Neobac?

A: Regulatory warnings focus on the Neomycin component. Neomycin is associated with the risk of cutaneous sensitization (allergic rash) and, rarely, systemic toxicities (ototoxicity and nephrotoxicity) upon significant absorption, which are the basis for patient and regulatory concern.


Q: Can I use Neobac if I have a history of depression or anxiety?

A: A history of depression or anxiety is not listed as a contraindication or a necessary precaution in the official labeling for this topical product.


How should Neobac be stored and disposed of?

Storage and Disposal Requirements

Official regulatory labeling dictates specific conditions for storing Neobac (Bacitracin and Neomycin combination) to ensure product stability and safety. The product must be stored at controlled room temperature, generally defined as between 15 C and 30 C (59 F and 86 F).

Storage Requirement Classification
Temperature Controlled Room Temperature
Prohibited Environment Protect from freezing
Container Rule Keep tightly closed when not in use
Child Safety Keep out of reach of children

The container must be kept tightly closed when not in use. It is a mandatory requirement to keep the medicine out of reach of children. Unused or expired product should be disposed of according to local regulations. In the event of accidental ingestion, immediate contact with a Poison Control Center or medical help is required.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Neobac found in:

A-Z Index: